Business Wire

TX-FLUENCE

Share
Fluence Selected as LED Technology Partner by Major Cannabis Cultivators in Growing Portuguese Market

Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, is supporting widespread expansion of pharmaceutical-grade medical cannabis cultivation operations in Portugal.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005215/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fluence LEDs in action at the Key Leaves facility in Portugal (Photo: Business Wire)

Portugal’s cannabis laws are among the most progressive in the world, and its established licensing system is ahead of most other European countries. Portugal decriminalized personal cannabis use in 2001 and legalized medical use in 2018. Since then, 20 official licenses for medical cannabis production, processing, import, export or a combination of categories have been issued, and Fluence has been chosen to provide lighting for over half of them.

Key Leaves, a medical cannabis market leader in Portugal, is one of the 20 companies to have received a medical cannabis license from the Portuguese government. The company is focused on delivering premium quality medicinal cannabis products that adhere to the Good Agricultural and Collection Practice (GACP) and Good Distribution Practices (GDP) wholesale standards, along with all relevant Portuguese regulations.

As a fully indoor facility dedicated to research and development, Key Leaves depends on sole-source lighting for its success—completing more than 20 full cultivation cycles using Fluence LED technology. Fluence’s LEDs have helped Key Leaves optimize production and cultivation light cycles, increase plant yield, uniformity and decrease energy consumption.

“To achieve our business objectives using the most effective and efficient production processes possible, we’ve invested in the world-class technologies and partnerships available,” said Alessandro Radici, CEO at Key Leaves. “Fluence’s market-leading LED technology and the on-call support of its research and horticulture teams allow us to cultivate with maximum efficacy, deliver a highly standardized product and guarantee constant supply for our clients.”

Fluence provides LED lighting solutions to 10 other licensed Portuguese medical cannabis producers—including Bathera, Curaleaf International and Clever Leaves, and pre-licensed AceCann—as well as several additional companies that are currently seeking licensing. Bathera, a German company, recently began producing its own medical cannabis and decided to construct its indoor cultivation and manufacturing facility near Lisbon. The site, currently in progress, houses 6,000 square meters of rooms dedicated to cultivation and 3,000 square meters of space for supporting areas, such as a GMP zone, six drying rooms and space for hand trimming and manual packaging.

“Because of the great Portuguese weather, outdoor cultivation is, of course, possible. We performed rigorous research and analysis with every construction decision and, after looking at the various options, we decided that cultivating indoors is the only way to ensure stable, high-quality products,” said Boris Agababov, founder and CEO of Bathera.

Curaleaf International focuses on advancing the therapeutic value of cannabis used for medicinal purposes to develop products that meet the needs of patients across Europe. The company’s commitment to accessibility, research and data-led product excellence brought it to Fluence when a lighting partner was needed for its Portuguese operations.

“Fluence’s goal is to help our customers grow smarter and build efficient economies of scale,” said Jörg Meyer-Brenken, lead account manager of cannabis in EMEA at Fluence. “We are led by science, and the collaborative approach we take to provide our partners with tailored lighting solutions, knowledge and experience has proven irreplaceable, especially for those in emerging medicinal cannabis markets.”

Portuguese native André Lagareiro, Fluence’s dedicated account manager for Portugal, works closely with Fluence’s Portuguese customers to help them identify the right lighting solutions to optimize plant growth and facility operations.

“Helping companies to innovate and advance medical cannabis operations within Portugal’s legislative environment requires a deep understanding of both cannabis cultivation and European regulatory standards,” said Lagareiro. “The unmatched top-of-the-line product, market expertise and quality of service provided by Fluence’s in-house research and development team is the deciding factor for the many Portuguese cannabis companies that have chosen Fluence as their lighting technology partner.”

For more information on Fluence, visit www.fluence.science.

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.

About AceCann

AceCann is a Portuguese medical cannabis company that has a cost-efficient, scalable and superior quality organic indoor cultivation and extraction facility near Lisbon. AceCann is focused on the development of new medical delivery forms for cannabis, joining efforts with local and international universities and operating on a flexible structure capable of making fast decisions to scale according to market demands and needs.

About Key Leaves

Key Leaves is a Portuguese-founded company established in 2015 and licensed by Infarmed for the cultivation, import and export of cannabis products. With a multicultural and diversified international team, Key Leaves is proud to be working with some of the most renowned professionals and experts in the medicinal cannabis field.

About Bathera

Bathera is a vertically integrated medical cannabis company with operations in Germany and Portugal. In addition to its state of the art indoor medical cannabis growing facility in Portugal, Bathera, operates two independent wholesalers and importers for medical cannabis in Germany.

About Curaleaf

Curaleaf International (formerly EMMAC Life Sciences Group) is Europe’s largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, Curaleaf International’s vision is to bring the life-enhancing potential of cannabis to the people who need it. EMMAC Life Sciences was acquired by Curaleaf Holdings in March 2021. For more information about Curaleaf International, please visit www.curaleafinternational.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005215/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis2.12.2025 12:32:00 CET | Press release

Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003, an IL‑2⍺-biased mutein designed to selectively activate Tregs while limiting effector T cell stimulation, as a potential treatment for atopic dermatitis. The open-label, multi-center Phase 1 trial begins with a single ascending dose portion in healthy volunteers to rapidly generate foundational safety, pharmacokinetic (PK), and pharmacodynamic (PD) data. These findings will inform dose selection and scheduling for the subsequent multiple ascending dose portion in approximately 40 adults with atopic dermatitis (AD), which will evaluate safety, PK/PD, and early clinical activity versus placebo. Data from both study segments are expected to guide dose selection for a planned Phase 2a trial in AD aimed at establishing clinical pro

AI Takes Center Stage as the Major Threat to Cybersecurity in 20262.12.2025 12:00:00 CET | Press release

Experian releases its 13th Annual Data Breach Industry Forecast highlighting six predictions for 2026 that include several ways AI may have an impact Experian® today released its 2026 Data Breach Industry Forecast, offering a look at the evolving cyber threat landscape. The predictions address how the coming year could usher in a new wave of sophisticated attacks driven by artificial intelligence along with other threats and vulnerabilities including quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202474758/en/ Experian's 2026 Data Breach Industry Forecast Now in its 13th year, the forecast offers six insights into how cybercriminals are leveraging emerging technologies to create more convincing identities, evade detection, and exploit new digital frontiers. From synthetic profiles and autonomous AI agents to shape-shifting malware and even brain-computer interface vulnerabilities, the 2026 predictions p

Buro Happold Signs Landmark Agreement with Expo 2030 Riyadh Company to Deliver Detailed Master Plan and Infrastructure and Public Realm Design for Expo 2030 Riyadh2.12.2025 11:00:00 CET | Press release

Buro Happold, a leading global engineering, design and advisory consultancy, has signed a major contract with Expo 2030 Riyadh Company to serve as the lead design consultant for the detailed master plan and detailed design of public realm, landscape, infrastructure and utilities for Expo 2030 Riyadh and its legacy. This partnership represents a significant step toward delivering an event billed as “An Unprecedented World Expo”. Expo 2030 Riyadh is expected to feature nearly 197 participating countries and attract over 42 million visits to Pavilions covering approximately 6 million sqm. The event will offer a unique opportunity for participants to address shared challenges and showcase pioneering solutions for a sustainable future. Under the agreement, Buro Happold will provide comprehensive design and technical services, including, development of the detailed master plan, including a focus on event requirements and legacy phase elements, detailed design of the infrastructure works, uti

ThetaRay Report Warns Europe’s AML System at ‘Breaking Point’ as New Regulations Make AI Adoption Inevitable2.12.2025 11:00:00 CET | Press release

Study by EU regulatory expert Prof. Andrea Minto and ThetaRay VP Regulatory Affairs Yaron Hazan finds legacy AML tools unfit for Europe’s new regulatory era ThetaRay, a global leader in Cognitive AI financial crime compliance, today released a landmark study on the future of anti-money laundering in Europe. The study warns that Europe’s anti-money laundering (AML) system is approaching structural failure, and that financial institutions will be unable to meet upcoming supervisory expectations without advanced AI-driven monitoring and customer screening systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202058684/en/ Next Generation AML Solutions The report, “Next-Generation AML Solutions: An Analysis of AI-Based Tools vis-à-vis the Reform of the European AML Institutional and Substantive Architecture,” offers some of the most comprehensive examinations to date of how the EU’s sweeping AML reform package and the Artif

Siren Secures Investment to Advance AI-Driven Investigations for National Security2.12.2025 10:30:00 CET | Press release

Decade-Long Partnership Expands Unified Platform For Agencies To Combat Complex Threats Siren, the all-in-one investigation company, today announced a strategic investment from Elastic (NYSE: ESTC), the company behind Elasticsearch. The investment deepens a decade-long partnership between the two companies and accelerates development of Siren’s AI-driven platform, including Siren’s newly launched K9 AI Companion, used by national security, law enforcement, and financial crime agencies worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202354147/en/ Siren, the all-in-one investigation company, today announced a strategic investment from Elastic (NYSE: ESTC), the company behind Elasticsearch. The partnership combines the Elasticsearch Platform, which delivers real-time search, retrieval and anomaly detection across structured, unstructured, and streaming data, with Siren’s patented investigative intelligence technolo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye